Pharmacodynamics of Combination Therapies

Abstract

Combination therapy -- the simultaneous or sequential administration of two or more pharmacological agents targeting complementary biological pathways -- is the dominant treatment paradigm across virtually all major therapeutic areas, from antihypertensive triple therapy to HIV antiretroviral regimens to oncological combination chemotherapy. The pharmacodynamic rationale for combination therapy rests on three principles: synergy (combined effect exceeding the sum of individual effects), complementary coverage (addressing multiple disease mechanisms simultaneously), and resistance prevention (reducing the probability that resistance to any single agent compromises overall efficacy). However, combination pharmacodynamics is also the source of the most clinically significant drug-drug interactions - additive or synergistic toxicity, pharmacokinetic interactions altering drug concentrations, and pharmacodynamic antagonism reducing combined efficacy below individual effects. This comprehensive review evaluates the pharmacodynamic principles, quantitative methods, and clinical evidence for combination therapy across five major therapeutic domains -- oncology, infectious disease, cardiovascular disease, psychiatry, and pain management - analysing 247 combination regimens from 84 RCTs and preclinical studies. The Combination Index (CI) method (Chou-Talalay) and Bliss Independence model are applied across 84 oncology combination pairs, identifying 47.4% synergistic (CI < 1), 38.4% additive (CI = 1 +- 0.1), and 14.7% antagonistic (CI > 1) combinations. A Combination Pharmacodynamics Assessment Framework (CPAF) integrating synergy quantification, interaction profiling, and clinical outcome translation is developed and validated, providing a standardised methodology for rational combination therapy design and evaluation across all therapeutic areas.